By Leroy Leo and Khushi Mandowara - U.S. Food and Drug Administration staff on Wednesday said data from a late-stage trial of Eisai and Biogen's Alzheimer's disease drug suggests it offered a meaningful benefit to patients and safety concerns likely would not hamper its chances of a traditional approval.
Analysts said the documents seemed to suggest approval for the drug. The FDA decision is expected by July 6. Eisai's application for a full approval is based on data showing Leqembi slowed the rate of cognitive decline in patients with early Alzheimer's by 27% compared to a placebo. The staff asked panelists to discuss the risk of serious side effects associated with the use of Leqembi in patients with a hard to diagnose condition called cerebral amyloid angiopathy, in which the protein amyloid that the drug targets builds up in the walls of arteries in the brain.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: IntEngineering - 🏆 287. / 63 Read more »
Source: FoxNews - 🏆 9. / 87 Read more »